Dasatinib (BMS-354825)

Dasatinib (BMS-354825) is an inhibitor of c-Kit and SRC used in studies of MAPK / ERK Signaling and Apoptosis and related signaling programs. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and caspase-associated cell-death signaling and survival decisions in angiogenesis, apoptosis, and autophagy models.

By inhibiting c-Kit and SRC, Dasatinib (BMS-354825) can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and caspase-associated cell-death signaling and survival decisions. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In angiogenesis, apoptosis, and autophagy models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving c-Kit and SRC
• Pathway perturbation studies connected to MAPK / ERK Signaling and Apoptosis and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Dasatinib (BMS-354825) is appropriate when a defined chemical perturbant is needed to connect c-Kit and SRC with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis, apoptosis, and autophagy models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.